Navigation Links
Class of Chemotherapy Drugs Helps Certain Breast Cancer Patients
Date:12/26/2007

Anthracyclines increase survival for HER2-positive tumors, but not negative ones, analysis finds,,

WEDNESDAY, Dec. 26 (HealthDay News)-- Chemotherapy drugs known as anthracyclines help boost survival for women with HER2-positive breast cancer who have undergone surgery, but they may not offer any survival benefit for those with HER2-negative tumors.

That's the conclusion of a wide-ranging analysis that pooled the results of eight randomized trials that compared the drugs with non-anthracyclines and took into account the women's HER2 status.

HER2-positive cancers test positive for a protein called human epidermal growth factor receptor 2 (HER2) and tend to grow quickly, the researchers said.

Since anthracyclines (such as doxorubicin and epirubicin) were introduced in the 1980s, they have been widely used as supplementary chemotherapy for breast cancer, said Dr. Alessandra Gennari, a medical oncologist at the National Cancer Research Institute in Genoa, Italy, and lead author of the study.

But the new analysis may change that, Gennari said. "Our study provides convincing statistical evidence that the added benefit of adjuvant chemotherapy with anthracyclines is confined to women who have breast tumors in which HER2 is overexpressed or amplified," she said.

"Since only about 25 to 30 percent of all breast cancers are HER2-positive, the vast majority of patients, with HER2-negative disease, may be spared unnecessary toxicities related to the use of this class of agents," she added.

The study findings were published online Dec. 25 in the Journal of the National Cancer Institute.

Anthracyclines have been associated with an increased risk of heart damage in some patients -- a risk doctors have known about for some time. An increased risk of leukemia, which can strike years later, is also associated with use of the drugs.

But, Gennari said, anthracyclines came into
'/>"/>

Copyright©2007 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Kingfisher Healthcare (KFH) Achieves World Class Quality Platform
2. ADDA Kicks Off AD/HD Awareness Campaign with Four Regional Conferences Beginning Sept. 29 and Series of Fall Teleclasses
3. A classic method for modeling skin cancer is featured in Cold Spring Harbor Protocols
4. First Circuit Court of Appeals Rules Against Philip Morris in Lights Class Action
5. Theater Classes Help Docs Bedside Manners
6. Tarpinian: Misclassification is Theft
7. New class of RNA molecules may be important in human cancer
8. Instrumentation Laboratory Named Top of Class by Respiratory Care Managers
9. Consumer Group: Hillary Clintons Mandatory Health Insurance Purchase Plan is an Act of War on the Middle Class Family That Cant Afford $12k Policy
10. SATELLITE BROADCAST: Consumer Group Says Hillary Clintons Mandatory Health Insurance Plan is an Act of War on the Middle Class that Cant Afford $12k Policy
11. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against LCA-Vision Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Class of Chemotherapy Drugs Helps Certain Breast Cancer Patients
(Date:8/1/2015)... TX (PRWEB) , ... August 01, 2015 , ... BeverlyD, ... for the March4thforWellBeing foundation, making hers the very first small business donation to kick ... look beautiful for over thirty years. Her legacy includes a complete line of raw, ...
(Date:7/31/2015)... ... July 31, 2015 , ... That’s right, ... are the STASH awards? The Significant Technological Achievements in Secretive Horticulture (or STASH) ... well as tried-and-true products that have stood the test of time. These include ...
(Date:7/31/2015)... , ... August 01, 2015 , ... The Honor Society ... Advisory Panel on the Future of Nursing (GAPFON) 20-21 July 2015 in San Juan, ... participate in this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied Health Personnel ...
(Date:7/31/2015)... ... 31, 2015 , ... Precision Aesthetics is New York’s only Thermage skin tightening ... first provider of Exilis non-surgical fat reduction in New York. Due to its ... large International clientele. Many patients travel to New York to get their non-surgical ...
(Date:7/31/2015)... ... , ... The 2nd annual Ride to Fight On will start and end ... The Ride to Fight On is a cycling fundraiser that benefits the West Cancer ... and The University of Tennessee Health Science Center. A health and wellness festival featuring ...
Breaking Medicine News(10 mins):Health News:March4thforWellBeing Foundation Kickoff 2Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3
... Than 33 Percent Traffic GrowthJERSEY CITY, N.J., March ... interactive marketing company that specializes in connecting health ... announced strong growth during 2008, along with significant ... site QualityHealth.com. The Company has used the down ...
... Exhibit , www.donaldverger.com PORTLAND, Maine, March 3 A ... a period of three days at the start of the ... compelled to turn his experience into something positive. , ... Verger for using his considerable talents to help the Innocence ...
... ANGELES, March 3 Dr. Brian S. Boxer Wachler, ... the Boxer Wachler Vision Institute in Beverly Hills, California, ... that uses vitamin applications to treat Keratoconus, an often ... patients. Dr. Boxer Wachler,s new treatment, C3-R(R) (corneal ...
... caused by faulty signalling in the brain, according to ... Psychiatry . In the biggest study of its kind, ... people with the condition have identified 49 genes that ... to controls. , Many of these genes are involved ...
... premier surgical and medical equipment supplier, now sells its DRE Integra AV-S ... be utilized as patients attempt to breathe spontaneously. , ... (Vocus) March ... of the Year by Business First of Louisville, continues expanding its ...
... scientists receive prestigious research fellowships worth US$1.5 million each , ... ... scientists have been awarded research grants from the National Research Foundation ... Singapore. These scientists hail from six nations including China, Estonia, ...
Cached Medicine News:Health News:Marketing Technology Solutions Announces Strong 2008 Growth and Web Site Enhancements for QualityHealth.com 2Health News:Victim of Mistaken Identity, Critically Acclaimed Photographer and Museum Founder to Hold Benefit for the Innocence Project 2Health News:Victim of Mistaken Identity, Critically Acclaimed Photographer and Museum Founder to Hold Benefit for the Innocence Project 3Health News:Victim of Mistaken Identity, Critically Acclaimed Photographer and Museum Founder to Hold Benefit for the Innocence Project 4Health News:New Vitamin Treatment Saves Patients (Including a U.S. Olympic Athlete) from Blinding Eye Disease Without Surgery 2Health News:New Vitamin Treatment Saves Patients (Including a U.S. Olympic Athlete) from Blinding Eye Disease Without Surgery 3Health News:Schizophrenia linked to signaling problems in new brain study 2Health News:DRE AV-S Ventilator Now Has Multiple Spontaneous Breathing Modes 2Health News:DRE AV-S Ventilator Now Has Multiple Spontaneous Breathing Modes 3Health News:DRE AV-S Ventilator Now Has Multiple Spontaneous Breathing Modes 4Health News:Singapore Offers Grants to Research Scientists to Start Labs Here 2Health News:Singapore Offers Grants to Research Scientists to Start Labs Here 3
(Date:7/30/2015)...  Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... the t:slim® and t:flex™ Insulin Pumps, today announced ... with Dexcom, Inc. to allow the integration of ... G5 and G6 continuous glucose monitoring ("CGM") systems. ... with Dexcom,s future CGM systems is an important ...
(Date:7/30/2015)... OAKS, Calif., July 30, 2015  Amgen (NASDAQ: ... the second quarter of 2015. Key results include: ... the second quarter of 2014 to $5,370 million, ... by Enbrel ® (etanercept), Prolia ® ... (carfilzomib) and XGEVA ® (denosumab). Unfavorable changes ...
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. ... the United States , European Union ... EMA and MHLW, respectively) for eribulin, for the treatment ... have received prior chemotherapy for advanced or metastatic disease. ... data from a pivotal global Phase 3 clinical trial ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... Oncobiologics announced today that it has signed two ... early-stage biotech company, and involves worldwide licensing for an ... based large pharmaceutical company to conduct research focused on ... The identity of the client firm was not disclosed ...
... Oct. 13, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. ... China-based advanced in-vitro diagnostic ("IVD") company, today announced that ... approved the Company,s real-time PCR-based V-Ki-ras2 Kirsten rat sarcoma ... as a companion diagnostic test for the use of ...
Cached Medicine Technology:Oncobiologics, Inc. Announces Two New Agreements Worth Close to $80 Million 2China Medical Technologies Receives SFDA Approval for its PCR-based KRAS Assay for Colorectal Cancer Targeted Drug 2
Double-ended. Semi sharp. Curved 3 mm tips. Angled right and left....
Double-ended. 6 mm x 9 mm and 6 mm x 11 mm tips....
Double-ended. 4 mm x 10 mm flat edge like scraper and 2 mm x 11 mm semi sharp tip....
Designated most popular model or size. 3 mm tip....
Medicine Products: